Organisation paid for research Program year 2025 Source: CMS Open Payments

Childrens Oncology Group

Neither a doctor nor a teaching hospital

Research payments

$1,224,353

7 payments

Through program year 2025, Childrens Oncology Group is reported as receiving $1,224,353 in research payments, across 7 payments.

By program year

3 rows
Year Kind Amount Payments
2025 Research $382,507 1
2024 Research $828,645 5
2023 Research $13,200 1

Breakdown

Who paid Research payments · program years 2023–2025
  1. AstraZeneca UK Limited $761,153 2 payments
  2. Pfizer Inc. $450,000 4 payments
  3. Adaptive Biotechnologies Corporation $13,200 1 payment
Studies the money was for Research payments · program years 2023–2025
  1. A Phase 3 Randomized Study of Selumetinib versus Carboplatin Vincristine in Children with Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 NF1 associated Low Grade Glioma LGG $761,153 2 payments
  2. Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy With Io Therapy for Children and Adults With Newly Diagnosed Stage I and II CHL $450,000 4 payments
  3. Cog_Aall1731_R $13,200 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record